Kornimate/medical-research-clean huggingface dataset:
deep learning in classifying bowel obstruction radiographs

Conditions: Digestive System Disease; Polyp of Colon; Bowel Disease

Summary: background: accurate labeling of obstruction site on upright abdominal radiograph is a challenging task. the lack of ground truth leads to poor performance on supervised learning models. to address this issue, self-supervised learning (ssl) is proposed to classify normal, small bowel obstruction (sbo), and large bowel obstruction (lbo) radiographs using a few confirmed samples. methods: a few number of confirmed and a large number of unlabeled radiographs were categorized based on the ground truth. the ssl model was firstly trained on the unlabeled radiographs, and then fine-tuned on the confirmed radiographs. resnet50 and vgg16 were used for the embedded base encoders, whose weights and parameters were adjusted during training process. furthermore, it was tested on an independent dataset, compared with supervised learning models and human interpreters. finally, the t-sne and grad-cam were used to visualize the model's interpretation.


Eligibility criteria:
inclusion criteria: 1. the hospital imaging system looked for plain abdominal standing films diagnosed as intestinal obstruction or normal between 2022 and 2024 2. aged 18 to 80 years 3. the main complaint was gastrointestinal symptoms exclusion criteria: 1. image interference, fuzzy performance, difficult to distinguish 2. non-gastrointestinal symptoms were the main complaint 3. supine, prone, or lateral decubitus radiography 4. paralytic obstruction, closed loop obstruction, et al

Keywords: deep learning artificial intelligence machine learning
barriers to therapeutic exercise in breast cancer patients before, during, and after chemotherapy

Conditions: Breast Cancer

Summary: cancer is one of the leading causes of mortality. first-choice cancer treatments, such as chemotherapy, have increased the survival of people with cancer, although they are not without adverse effects such as cardiotoxicity, fatigue, nausea, mental health problems or musculoskeletal disorders. therapeutic exercise is a safe and effective intervention that has shown positive results in the oncology population when implemented as an adjuvant to chemotherapy, during or after chemotherapy. exercise improves cardiorespiratory capacity, fatigue, strength, anxiety, depressive symptoms and quality of life, among others, in cancer patients. in the implementation of therapeutic exercise in the oncologic population undergoing chemotherapy treatment, it is necessary to take into account possible barriers related to the perception of therapeutic exercise, as well as the side effects derived from chemotherapy. it is necessary to know the barriers to the implementation of exercise in order to address them and favor patients' adherence to exercise programs. the objective is to identify the barriers (physical, contextual and emotional) that may influence people with breast cancer who are in the pre-, concurrent or post-treatment phase, respectively, of chemotherapy treatment for the implementation of therapeutic exercise. the study participants (n=111) will be distributed in the study groups according to the moment of chemotherapy treatment they are in (1: pre-chemotherapy, 2: during chemotherapy, 3: post-chemotherapy).


Eligibility criteria:
inclusion criteria: * women over 18 years of age with a diagnosis of breast cancer, stages i to iiia. * the sample will be distributed to three groups according to the time of treatment in which the patients are: a) patients diagnosed with breast cancer scheduled to start chemotherapy treatment, b) patients who at the time of the study are receiving chemotherapy and c) patients who have completed chemotherapy treatment 6 months ago or more. exclusion criteria: * women with breast cancer relapse and/or other types of cancer. * patients who are receiving hormonal therapy at the time of evaluation. * patients presenting metastatic processes or any other relevant disease.

Keywords: breast cancer chemotherapy barriers to exercise physical activity fatigue
the changes of ryodoraku and hrv after ppi treatment in gerd patients

Conditions: Non-erosive Reflux Disease; Barrett's Esophagus

Summary: gastroesophageal reflux disease(gerd) mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. proton pump inhibitors (ppi) can effectively block gastric acid secretion but the drug reactions and the degree of improvement in symptoms are sometimes unpredictable. the aim of this study is to investigate the association between the clinical efficacy of ppi in patients with gerd and the personal physical status by ryodoraku and answatch.

gastroesophageal reflux disease(gerd) is a common disease, mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. the common symptoms of gerd are heartburn, acid regurgitation, chest pain and globus hystericus. the methods to treat gerd are changes of lifestyle, pharmacotherapy, antireflux surgery and endoscopy. proton pump inhibitors (ppi) can effectively block gastric acid secretion and promote the repair of esophagus, but the drug reactions and the degree of improvement in symptoms are sometimes unpredictable. recently there are many instruments used to analyze personal physical status. meridian energy analysis device ( ryodoraku ) is used to assess the energy of meridian system by analysis of resistance of the skin surface, as well as the wrist-worn heart rate monitor (answatch) used to assess the autonomic nervous system by analysis of heart rate variability. therefore, the aim of this study is to investigate the association between the clinical efficacy of ppi in patients with gerd and the personal physical status by ryodoraku and answatch. investigators will recruit 120 patients with gerd in clinic who have to receive ppis for four weeks and assess each volunteer before and after taking the medication. assessment methods : 1. answatch to assess the autonomic nervous system, 2. ryodoraku to assess the energy of meridian system, 3. upper gastrointestinal endoscopy to assess the grade of reflux esophagitis, 4. gastroesophageal reflux disease questionnaire to assess the severity of gerd. investigators analysed and compared the database from the assessments between before and after taking the medication. investigators anticipate to substantiate that the changes of ryodoraku and answatch are good predictors for the clinical efficacy of ppi in patients with gerd.

Eligibility criteria:
inclusion criteria: * male or female * age of 20-75 years * patients with gerd who have to receive ppis for four weeks exclusion criteria: * suffering from peptic ulcer, gallstones, cancer, and barrett's esophagus * previously underwent the esophagus, stomach or duodenum surgery * lactating women or pregnant women

Keywords: ryodoraku meridian energy heart rate variability autonomic nervous system gerd
safety and pharmacokinetics/pharmacodynamics of shr3824 in patients with hepatic impairment

Conditions: Hepatic Impairment

Summary: comparison of the pharmacokinetics/pharmacodynamics of the shr3824 in patients with mild, moderate and severe hepatic impairment compared with healthy volunteers.


Eligibility criteria:
inclusion criteria: * 18 years to 75 years (inclusive) * body mass index should be between 18 and 33 kg/m2 (inclusive) (ie, a measure of one's weight in relation to height) * liver damage due to viral hepatitis, alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis of the liver (except for patients with drug-induced liver injury) exclusion criteria: * allergic to sglt2 inhibitor analogues or any other similar structure; * lactose intolerance history or lactose intolerance; * suspected or diagnosed as liver cancer or with other malignant tumors; * alcoholic liver, autoimmune liver disease, liver transplantation history
bandage contact lens application for the management of corneal abrasion

Conditions: Corneal Abrasion

Summary: the researchers are trying to understand if the application of a bandage contact lens results in better relief than usual treatment for a corneal abrasion.


Eligibility criteria:
inclusion criteria: * diagnosis of superficial corneal abrasion exclusion criteria: * incarceration * pregnancy * inability to provide informed consent * infectious keratitis * retained foreign bodies in the eye * active infection involving the orbit or periorbital region * patients who are not able to or who are deemed unlikely to follow-up with ophthalmology * a history or recent contact lens wear * a lack of trauma or an unclear history of trauma as the inciting cause of the abrasion * allergy to the antimicrobial solution (polytrim) * women who are currently breastfeeding * chronic eye drop use * a history of eye surgery other than cataract surgery (greater than 6 months prior to abrasion) * diabetes (patients with even mild diabetic neuropathy can have decreased pain sensation and also delayed corneal epithelial healing) * any eye condition that may be deemed to interfere with the conduct of the protocol or outcome measurement.
low dose naltrexone (ldn) immune monitoring

Conditions: Fibromyalgia

Summary: we have found that low dose naltrexone (ldn) can substantially reduce pain associated with fibromyalgia syndrome. we believe ldn may work via novel anti-inflammatory channels. the purpose of this study is to determine if ldn lowers inflammatory markers in individuals with fibromyalgia.

eligible women with fibromyalgia (fm) will be enrolled into a 10-week drug trial. during the first two weeks, a baseline phase will be used to collect data on immune function and symptoms. ldn will be administered for 8 weeks. although there is no placebo arm built-in, participants will be advised that they may receive a placebo during the trial. participants will provide twice daily symptom reports using an android tablet device and dooblo surveytogo survey software. participants will also provide a blood sample twice every week for the duration of the study. plasma inflammatory markers will be tested using a luminex based 63-plex inflammatory assay panel. the primary aim of the study is to test if 8 weeks of ldn administration is associated with a reduction in pro-inflammatory markers in plasma in women with fm.

Eligibility criteria:
inclusion criteria: * females age 18-65 * meets criteria for 1990 acr criteria for fibromyalgia * able to receive venous blood draw twice a week for 16 weeks * sufficient symptom variability during baseline report * patient completes daily report during 2 week baseline period at least 80% completion rate. exclusion criteria: * opioid use * significant psychological comorbidity that in the discretion of the investigator compromises study integrity * location prohibits travel to stanford * blood or clotting disorder * rheumatologic or autoimmune disease * acute infection * baseline blood esr \>60, crp greater than 3.0mg/l, positive rheumatoid factor, or positive ana * use of blood thinning medication * pregnant or currently planning to become pregnant * current use of aspirin, ibuprofen, naproxen, or other confounding-anti-inflammatory medication as part of regular medication regimen. * known allergy to naltrexone or naloxone * currently participating in another treatment-based research study * self-reported inability to refrain from alcohol for the duration of the study period
cluster rct of co-administration azithromycin, albendazole & ivermectin

Conditions: Trachoma; Lymphatic Filariases

Summary: cluster-randomised trial comparing co-administration of azithromycin/ivermectin/albendazole with separate administration of azithromycin and ivermectin/albendazole. the study will be conducted in beneshangul-gumuz region, ethiopia. within this district, a study group of 8,000 people (in approximately 40 clusters) will receive the azithromycin, ivermectin \& albendazole at a single time. a control group of 8,000 people (in approximately 40 clusters) within the same district will receive the current mda treatment schedule beginning with ivermectin/albendazole followed two weeks later with azithromycin. all drug dosing will be in line with standard fmoh and who guidelines for mda for trachoma and lymphatic filariasis. the study will randomly sort subdistrict communities (gotes) into the trial arm and the control arm. the study will compare the number of adverse events (aes) and severe adverse events (saes) between the two arms to determine if co-administration is not inferior to the standard treatment. the primary outcome will be to demonstrate the safety of the triple-drug administration as measured by incidence of aes/saes following the mda.


Eligibility criteria:
inclusion criteria: 1. residing in the community for at least three months; 2. eligible to receive all three agents according to standard mda criteria exclusion criteria: 1. not eligible to receive one or more drugs according to standard mda criteria; 2. less than 5 years of age (not eligible for ivermectin)\*\* 3. pregnant women (azithromycin only, not eligible for albendazole and ivermectin) 4. lactating women (only administered azithromycin and albendazole, not eligible for ivermectin)\*\* 5. history of allergies to the drugs being studied (azithromycin, ivermectin, albendazole) 6. residents who cannot swallow tablets * note that patients that are not eligible for ivm, will receive azithromycin and albendazole. patients that receive azithromycin and albendazole will be followed up through the same procedure as the triple drug therapy to try to track any aes attributed to the two drug combination.
efficacy of pythagorean self-awareness intervention for major depressive disorder

Conditions: Major Depressive Disorder

Summary: the present study explored the effects of the implementation of the pythagorean self awarenes intervention (psai) on patients diagnosed with major depressive disorder. the primary aim was to evaluate the effectiveness of psai compared to the usual care provided for adults with major depressive disorder with respect to the reduction of depressive symptoms. secondary aims of this study included reduction of stress and anxiety, enhancement of healthy lifestyle and improvement of affect, sleep quality and cognitive functions of patients.

study design this randomized controlled trial was conducted at the mental health center of peristeri, department of the psychiatric hospital of attica, greece, from december 2018 to january 2020. the study protocol was approved by the school of medicine, national and kapodistrian university of athens (protocol n. 1718038002/30/07/2018) and the center's directorate and was consistent with the declaration of helsinki. all participants were enlisted in the study only after being fully informed by the researcher about the aims and procedures of the research and submitting written consent. procedures patients eligible for the above mentioned criteria were randomized in two groups: the intervention group, receiving psai, and the control group, receiving the usual care provided by the center for patients with mdd, namely medical treatment and counselling. randomization was conducted based on random numbers generated by an online random number generator (https://www.sealedenvelope.com/simple-randomiser/v1/lists). this study was non-blinded, as patients and researchers were aware of the group assignment.

Eligibility criteria:
inclusion criteria: * major depressive disorder diagnosis conducted by a psychiatrist of the center according to the dsm-v criteria * residency in attica * ability to speak and write fluently in the greek language exclusion criteria: * antecedent psychotic or manic episode * current feeding or eating disorder, obsessive-compulsive disorder, self-harming behaviors or recent suicide attempt and current drug abuse or addiction * current treatment with cognitive-behavioral therapy * denial to participate in the research

Keywords: major depression stress management program
spaceoar system rws in china

Conditions: Localized T1-T2 Prostate Cancer

Summary: this study aims to evaluate the safety and performance of spaceoar system when it is used to create space between the rectum and prostate in men undergoing radiotherapy for localized t1-t2 prostate cancer in china via collecting the real word data of spaceoar system used, to generate local clinical evidence on chinese patients.

this study is a retrospective and prospective, single arm, real world study. for those patients who have already received the spaceoar treatment before study kick-off, the data at baseline and the day of procedure will be retrospectively collected. for those patients who will receive spaceoar treatment after study kick-off, the clinical data at baseline, the day of procedure and 30 days post procedure will be prospectively collected. up to 20 subjects with a pathologically confirmed diagnosis of clinical stage t1 or t2 prostate cancer indicated for radiotherapy will be enrolled, for there are chances of missing data in the real world study. a sample of 14 subjects provides at least 90% power for the primary objective.

Eligibility criteria:
inclusion criteria: * subjects has provided the written informed consent, willing to participate in clinical data collection and willing to receive visit at 30 days post procedure. (for subjects enrolled prospectively) * subjects must have been pathologically confirmed prostate cancer with clinical stage t1-t2, and have been treated or will be treated with space oar hydrogel in hospital in hainan boao lecheng medical pilot zone. exclusion criteria- no specific exclusion criteria unless the patients refuse to sign the informed consent.
quantifying the efficacy and role of service dogs for military veterans with ptsd

Conditions: Post Traumatic Stress Disorder

Summary: the purpose of this study is to quantify the therapeutic efficacy and role of trained service dogs on socio-emotional functioning among military veterans with posttraumatic stress disorder (ptsd).

the long-term research goal is to evaluate the safety and efficacy of service dogs as a complementary intervention to enhance biopsychosocial functioning in special populations. the objective is to conduct a methodologically rigorous trial to quantify the therapeutic efficacy of service dogs on clinically-important outcomes for veterans with ptsd. based on preliminary findings and qualitative reports, the central hypothesis is that military veterans with ptsd who are provided service dogs will experience reduced ptsd symptoms related to socio-emotional functioning and arousal modulation. the rationale for this research is that its successful completion will provide an evidence-based demonstration of the efficacy and role of an increasingly used yet poorly tested complementary intervention. the completion of this project is expected to established an initial demonstration of the therapeutic efficacy of service dogs in this population, as well as possible mechanisms of action via specific biological pathways and human-canine interaction profiles.

Eligibility criteria:
inclusion criteria for veterans into the study will include: * applied for and approved to receive a dog from k9s for warriors * military service on or after september 11, 2001 * honorable discharge or current honorable service * diagnosis of ptsd * no conviction of any crimes against animals.

Keywords: service dogs human-animal interaction
partial-breast radiation therapy in treating women with early-stage breast cancer

Conditions: Breast Cancer

Summary: rationale: internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. it may also cause less damage to normal tissue. purpose: this phase ii trial is studying how well partial-breast radiation therapy works in treating women with early-stage breast cancer.

objectives: primary * to examine the efficacy of mammosite® radiation therapy system (rts) in delivering partial-breast irradiation to women with early-stage breast cancer. secondary * to assess the toxicities associated with mammosite® rts in these patients. * to evaluate the cosmetic results in the breast after brachytherapy with the mammosite® rts. * to correlate the cosmetic results with the use of chemotherapy, volume of the implant, and distance from the implant to the skin. * to correlate the local recurrence rate with time between surgery and implant. outline: patients undergo placement of the mammosite® radiation therapy system (rts) device into the cavity where the tumor was removed either at the time of surgery or percutaneously under ultrasound guidance after surgery. within 2-5 days after the device implant, patients undergo partial-breast irradiation delivered by mammosite® rts twice daily for 5 days. after completion of study therapy, patients are followed up periodically for 5 years.

Eligibility criteria:
disease characteristics: * histologically confirmed ductal carcinoma in situ (dcis) of the breast or invasive breast adenocarcinoma * stage 0, i, or ii (t2, n0; tumor size ≤ 3 cm) disease * pathologic staging of the axilla preferred * clinical staging of the axilla allowed for patients ≥ 70 years of age with hormone receptor-positive tumors * unicentric tumor * microscopic multifocality allowed as long as the total tumor size is ≤ 3 cm * must have undergone lumpectomy as definitive surgery * negative surgical margins, defined as no tumor at the inked margin of resection after final surgery * re-excision to obtain negative margins allowed * must have adequate skin spacing between balloon surface and surface of the skin and lung (≥ 7 mm) * no multicentric carcinoma (invasive or dcis) in more than one quadrant * no clinically or pathologically positive regional lymph nodes * no extensive intraductal component, defined as dcis extending beyond the primary invasive component into normal breast parenchyma and composing \> 25% of the primary tumor * hormone receptor status not specified patient characteristics: * menopausal status not specified * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no collagen-vascular disease, including any of the following: * dermatomyositis * systemic lupus erythematosus * scleroderma-mixed connective tissue disease prior concurrent therapy: * see disease characteristics

Keywords: ductal breast carcinoma in situ stage ia breast cancer stage ib breast cancer stage ii breast cancer
oto-313 in subjects with unilateral subjective tinnitus

Conditions: Subjective Tinnitus

Summary: the purpose of this study is to determine the efficacy of oto-313 in subjects with unilateral tinnitus and to determine the safety and tolerability of oto-313 in subjects with unilateral tinnitus.


Eligibility criteria:
inclusion criteria: * subject has early-onset subjective unilateral tinnitus that is persistent (consistently aware of their tinnitus throughout much of the waking day). * subject is able to use the diary to complete their daily tinnitus ratings. * subject's tinnitus is likely of cochlear origin, e.g., associated with sensorineural hearing loss; acute hearing loss from noise trauma, barotrauma, or traumatic cochlear injury (acute acoustic trauma, blast trauma, middle ear surgery, inner ear barotrauma); age related hearing loss; resolved otitis media; ototoxic drug exposure. * subject is willing to comply with the protocol and attend all study visits. exclusion criteria: * subject has pulsatile tinnitus, temporomandibular joint disease (tmj) associated with tinnitus perception, tinnitus resulting from traumatic head or neck injury, or tinnitus resulting from a tumor or stroke. * subject is pregnant, lactating, or undergoing fertility treatment. * subject has other clinically significant illness, medical condition or medical history at screening or baseline that, in the investigator's opinion, would likely reduce the safety of study participation or compliance with study procedures.

Keywords: intratympanic injection it injection gacyclidine tinnitus